LIV Emles at Home ETF

Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of innovative drugs, announced today, it has new preclinical data gathered in a series of animal studies that shows its Cardiovascular drug SP-1000 reduces blood cholesterol. Lowering cholesterol is a key component in the prevention and management of heart disease. Earlier preclinical "in vitro" studies gave Samaritan reason to believe its proprietary peptide SP-1000 cleans the blood of excessive cholesterol and corrects high cholesterol conditions in people affected by the disease. Advancing to animal preclinical studies, SP-1000 data indicated that it removes cholesterol from the LDL "bad" cholesterol-apolipoprotein complex and it reduced blood cholesterol levels in two different types of hypercholesterolemic "animal models." These models included genetically engineered and diet-induced hypercholesterolemic, animals. This new preclinical data is being prepared to submit to a peer-reviewed journal. Dr. Greeson, CEO of Samaritan stated, "The novelty of SP-1000 as a new cholesterol therapy lies in its 'mechanism of action,' that is SP-1000 eliminates excessive cholesterol directly from the blood; in contrast, to all known current cholesterol therapies where the mechanism of action entails the enzymes responsible for cholesterol synthesis in the liver. In addition, our drug comes at a time when quite a few of the cholesterol lowering statins are about to come off patent. We believe this is a drug that major pharmaceuticals will find compelling, as well as the patients who have extreme difficulty managing their cholesterol levels." Samaritan Pharmaceuticals: "We LIV....to Save Lives." Samaritan is a small-cap Biotech, driven to discover, develop, and commercialize, innovative therapeutics for AIDS, Alzheimer's, cancer and heart disease. Look at www.samaritanpharma.com. Please register on Website so we can notify you of upcoming conference calls, news and events. Disclaimer The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 15, 2005. The company undertakes no duty to update forward-looking statements.